Evidence map›Paper›PMID 32012171›Full record

ArticlePloS one2020

The role of melatonin on miRNAs modulation in triple-negative breast cancer cells.

Lívia C Ferreira, Francesca Orso, Daniela Dettori, Jéssica Z Lacerda, Thaiz F Borin, Daniela Taverna, Debora A P C Zuccari

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 33 citations in OpenAlex.

  1. Melatonin and Breast Cancer: A Review Article.Chonnam medical journal · 2025
    Review
  2. Review
  3. Role of Melatonin in Cancer: Effect on Clock Genes.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Melatonin: an endogenous miraculous indolamine, fights against cancer progression.Journal of cancer research and clinical oncology · 2020
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Lívia C FerreiraDepartment of Biology, Universidade Estadual Paulista "Júlio de Mesquita Filho", São José do Rio Preto, São Paulo, Brazil.
Francesca OrsoMolecular Biotechnology Center (MBC), Department Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Daniela DettoriMolecular Biotechnology Center (MBC), Department Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Jéssica Z LacerdaDepartment of Biology, Universidade Estadual Paulista "Júlio de Mesquita Filho", São José do Rio Preto, São Paulo, Brazil.
Thaiz F BorinDepartment of Biochemistry and Molecular Biology, Tumor Angiogenesis Laboratory, Augusta University, Augusta, Georgia, United States of America.
Daniela TavernaMolecular Biotechnology Center (MBC), Department Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Debora A P C ZuccariDepartment of Biology, Universidade Estadual Paulista "Júlio de Mesquita Filho", São José do Rio Preto, São Paulo, Brazil.
University of Turin · ITUniversidade Estadual Paulista (Unesp) · BRAugusta University · USFaculdade de Medicina de São José do Rio Preto · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melatonin, a hormone secreted by pineal gland, exerts antimetastatic effects by reducing tumor cell proliferation, migration and invasion. MicroRNAs (miRNAs) are small, non-coding RNAs that play a crucial role in regulation of gene expression and biological processes of the cells. Herein, we search for a link between the tumor/metastatic-suppressive actions of melatonin and miRNA expression in triple-negative breast cancer cells. We demonstrated that melatonin exerts its anti-tumor actions by reducing proliferation, migration and c-Myc expression of triple negative breast cancer cells. By using Taqman-based assays, we analyzed the expression levels of a set of miRNAs following melatonin treatment of triple negative breast cancer cells and we identified 17 differentially expressed miRNAs, 6 down-regulated and 11 up-regulated. We focused on the anti-metastatic miR-148b and the oncogenic miR-210 both up-regulated by melatonin treatment and studied the effect of their modulation on melatonin-mediated impairment of tumor progression. Surprisingly, when miR-148b or miR-210 were depleted in triple-negative breast cancer cells, using a specific miR-148b sponge or anti-miR-210, melatonin effects on migration inhibition and c-myc downregulation were still visible suggesting that the increase of miR-148b and miR-210 expression observed following melatonin treatment was not required for the efficacy of melatonin action. Nevertheless, ours results suggest that melatonin exhibit a compound for metastatic trait inhibition, especially in MDA-MB-231 breast cancer cells even if a direct link between modulation of expression of certain proteins or miRNAs and melatonin effects has still to be established.

Indexed as

Cell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMelatoninMicroRNAsProto-Oncogene Proteins c-mycTriple Negative Breast NeoplasmsMelatoninMicroRNAsMYC protein, humanProto-Oncogene Proteins c-myc

Identifiers

PMID32012171
PMCPMC6996834
OpenAlexW3004457953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.